Neuroendocrine Carcinomas Pancreatic Origin, Polish Experience Abstract #1934

Introduction: Pancreatic neuroendocrine carcinomas (NEC) including poorly differentiated (NECG3), mixed type (MANEC) and NETG3 are rare of pancreatic neuroendocrine neoplasms.
Aim(s): Retrospective analysis of records to determine natural history and outcomes OS and PFS in this group of NEN.
Materials and methods: Review of pancreatic poorly differentiated NEN 51 subjects (15,6%) selected. All patient data sets were review consider OS and PFS for clinical stage (CS) and pathological factors type of the cancer cells and Ki-67.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Jarosław Ćwikła

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2133 Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms
Introduction: The high grade pancreatic neuroendocrine neoplasms (PanNENs) include well-differentiated tumors (WD-NETs) with elevated proliferation and poorly differentiated carcinomas (PD-NECs).
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Vera Delektorskaya
#1568 Neuroendocrine Neoplasm of the Colon and Rectum, Pathological and Clinical Characteristics, Based on pTNM WHO 2010 Classification
Introduction: Large bowel neuroendocrine neoplasms (NENs)
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Jaroslaw Cwikła
#2121 Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy
Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: M.D., Ph.D. Yasushi Ichikawa
#1830 Increase of the Ki67 Proliferation Index over Time in Patients with Neuroendocrine Neoplasms
Introduction: Whether the Ki67 index increases over time in relation to progression is scarcely studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Pernille Holmager
#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)
Introduction: SSA are the first line therapy in well differentiated pNET
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Md, PhD Agnieszka Kolasińska-Ćwikla